UNCY

Unicycive Therapeutics, Inc.

Healthcare
Biotechnology
$107M market cap

Forecast run · Oct 29, 2026Upside rank 627 of 3,186

Model Signal

ForecastQ Daily Probabilities

41.9%

44.9%

34.8%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$3.89

Price target$22.00

Implied move+465.6%

Analysts8

ForecastQ Portfolios

UNCY is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.